UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 2041-12
Program Prior Authorization/Medical Necessity
Medication Eloctate® [antihemophilic factor (recombinant), Fc fusion protein]
P&T Approval Date 8/2014, 2/2015, 2/2016, 12/2016, 11/2017, 11/2018, 11/2019, 9/2020,
9/2021, 9/2022, 9/2023, 9/2024
Effective Date 12/1/2024
1. Background:
Eloctate [Antihemophilic Factor (Recombinant), Fc Fusion Protein] is a recombinant DNA
derived, antihemophilic factor indicated in adults and children with Hemophilia A (congenital
Factor VIII deficiency) for:1
On-demand treatment and control of bleeding episodes
o
Perioperative management of bleeding
o
Routine prophylaxis to reduce the frequency of bleeding episodes
o
Eloctate is not indicated for the treatment of von Willebrand disease.
2. Coverage Criteriaa:
A. Initial Authorization
1. Eloctate will be initially approved based on all of the following criteria:1,2
a. Diagnosis of hemophilia A
-AND-
b. Patient is not a suitable candidate for treatment with shorter acting half-life Factor
VIII (recombinant) products [Advate, Kogenate FS, Kovaltry, Novoeight, Nuwiq, or
Recombinate] as attested by the prescriber
-AND-
c. One of the following:
(1) Both of the following:
(a) Dose does not exceed 50 IU/kg
-AND-
(b) Patient is infusing no more frequently than every 4 days
© 2024 UnitedHealthcare Services, Inc.
1
-OR-
(2) Requested dosage regimen does not exceed 12.5 IU/kg/day
-OR-
(3) Both of the following:
(a) Patient is less than 6 years of age
-AND-
(b) One of the following:
i. Pharmacokinetic (PK) testing results suggest that dosing more intensive
than 50 IU/kg is required
-OR-
ii. PK testing results suggest that dosing more frequent than every 3.5 days is
required
-OR-
iii. PK testing results suggest that dosing more intensive than 14.5 IU/kg/day
is required
Authorization of therapy will be issued for 12 months.
B. Reauthorization
1. Elocate will be approved based on all of the following criteria:
a. Documentation of positive response to Eloctate therapy
-AND-
b. One of the following:
(1) Both of the following:
(a) Dose does not exceed 50 IU/kg
-AND-
(b) Patient is infusing no more frequently than every 4 days
© 2024 UnitedHealthcare Services, Inc.
2
-OR-
(2) Requested dosage regimen does not exceed 12.5 IU/kg/day
-OR-
(3) Both of the following:
(a) Patient is less than 6 years of age
-AND-
(b) One of the following:
i. PK testing results suggest that dosing more intensive than 50 IU/kg is
required
-OR-
ii. PK testing results suggest that dosing more frequent than every 3.5 days is
required
-OR-
iii. PK testing results suggest that dosing more intensive than 14.5 IU/kg/day
is required
Authorization of therapy will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply
3. Additional Clinical Programs:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-
10) and/or claim logic. Use of automated approval and re-approval processes varies by
program and/or therapeutic class.
4. References:
1. Eloctate® [package insert]. Waltham, MA: Bioverativ Therapeutics Inc., May 2023.
2. Mahlangu J, Powell JS, Ragni MV. Phase 3 study of recombinant factor VIII Fc fusion
protein in severe hemophilia A. Blood. 2014 Jan 16;123(3):317-25.
3. MASAC Recommendations Concerning Products Licensed for the Treatment of
Hemophilia and Selected Disorders of the Coagulation System. MASAC Document
#284, April 11, 2024.
© 2024 UnitedHealthcare Services, Inc.
3
Program Prior Authorization/Medical Necessity - Eloctate
Change Control
2/2015 New program. Version approved 8/2014 but implementation delayed.
2/2016 Annual Review. No changes to criteria. References updated.
12/2016 Annual Review. Updated short acting FVIII examples to preferred
products. Updated background and references.
11/2017 Annual review. Removed criteria pertaining to severity of hemophilia
A. Updated criteria pertaining to dosage regimens to allow for
increased flexibility in dosage regimen. Updated criteria to allow for
PK guided dosing in pediatric patients under 6 years old.
11/2018 Annual review. No changes to clinical coverage criteria. Updated
references.
11/2019 Annual review. No changes to clinical coverage criteria.
9/2020 Updated preferred standard half-life recombinant products. Updated
references.
9/2021 Annual review. No changes to clinical coverage criteria. Updated
references.
9/2022 Annual review. Added text “pharmacokinetic” to clarify abbreviation
“PK” with no changes to clinical intent. Updated references.
9/2023 Annual review. Modified physician attestation to prescriber attestation.
Updated references.
9/2024 Annual review. No changes to clinical coverage criteria. Updated
references.
© 2024 UnitedHealthcare Services, Inc.
4